Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

This study has been terminated.
(Based on PK data, product did not meet requirement for further development.)
Information provided by (Responsible Party):
ZARS Pharma Inc. Identifier:
First received: August 2, 2005
Last updated: June 4, 2012
Last verified: June 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2007
  Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)